Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more
Jw Life Science Corp (234080) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.053x
Based on the latest financial reports, Jw Life Science Corp (234080) has a cash flow conversion efficiency ratio of 0.053x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩11.29 Billion) by net assets (₩214.86 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jw Life Science Corp - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Jw Life Science Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jw Life Science Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jw Life Science Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sogefi S.p.A.
LSE:0NV0
|
0.384x |
|
ÖKOWORLD AG
F:VVV3
|
N/A |
|
Musti Group Oyj
HE:MUSTI
|
0.079x |
|
ZHOU HEI YA HLDG -000001
F:ZHY
|
N/A |
|
Jutal Offshore Oil Services Ltd
PINK:JUTOF
|
N/A |
|
Deltex Medical Group plc
PINK:DTXMF
|
-0.032x |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
-0.018x |
|
UVAT Technology Co Ltd
TWO:3580
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Jw Life Science Corp (2015–2024)
The table below shows the annual cash flow conversion efficiency of Jw Life Science Corp from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩200.44 Billion | ₩50.69 Billion | 0.253x | +7.28% |
| 2023-12-31 | ₩159.39 Billion | ₩37.57 Billion | 0.236x | +134.14% |
| 2022-12-31 | ₩140.33 Billion | ₩14.13 Billion | 0.101x | -56.11% |
| 2021-12-31 | ₩131.49 Billion | ₩30.17 Billion | 0.229x | -35.20% |
| 2020-12-31 | ₩132.06 Billion | ₩46.75 Billion | 0.354x | +78.82% |
| 2019-12-31 | ₩122.62 Billion | ₩24.28 Billion | 0.198x | -40.13% |
| 2018-12-31 | ₩109.26 Billion | ₩36.13 Billion | 0.331x | +53.12% |
| 2017-12-31 | ₩102.10 Billion | ₩22.05 Billion | 0.216x | +21.27% |
| 2016-12-31 | ₩90.30 Billion | ₩16.08 Billion | 0.178x | -43.04% |
| 2015-12-31 | ₩82.83 Billion | ₩25.90 Billion | 0.313x | -- |